We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| E-therapeutics Plc | LSE:ETX | London | Ordinary Share | GB00B2823H99 | ORD 0.1P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.05 | -0.56% | 8.80 | 8.80 | 9.95 | 9.00 | 8.80 | 8.85 | 791,667 | 09:36:18 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Coml Physical, Biologcl Resh | 475k | -8.27M | -0.0142 | -6.20 | 51.38M |
From Apr 2019 to Apr 2024
TIDMETX
RNS Number : 0166X
e-Therapeutics plc
16 February 2017
e-Therapeutics plc
('e-Therapeutics' or 'the Company')
Directorate Change
Oxford, UK, 16 February 2017 - e-Therapeutics plc (AIM:ETX) announced today that Sean Nicolson, Executive Director & Company Secretary will be leaving in order to focus on other business commitments.
Iain Ross, Chairman said:
"Over the last year this business has gone through a period of transition culminating with the recent announcement of the appointment of Dr. Raymond Barlow as our new CEO. During this period Sean has made a significant contribution and will leave the Company on 28 February. I would like to thank him personally for his support and to wish him every success in the future."
-Ends-
Contacts:
e-Therapeutics plc Tel: +44 (0) 1993 883 125 Iain Ross, Chairman www.etherapeutics.co.uk Steve Medlicott, Finance Director Numis Securities Limited Tel: +44 (0) 207 260 1000 Michael Meade / Freddie Barnfield (Corporate www.numis.com Finance) James Black (Corporate Broking) Instinctif Partners Tel: +44 (0) 207 457 2020 Melanie Toyne-Sewell / Alex Shaw Email: e-therapeutics@instinctif.com
About e-Therapeutics plc
e-Therapeutics (AIM: ETX) is a drug discovery company with a proprietary discovery platform based on advances in network pharmacology and chemical biology. The Company is applying its platform to the discovery of new drug candidates. The therapeutic focus of the Company's activity is in immuno-oncology, addressing drug resistance in targeted cancer therapies and anti-infectives. The platform is highly productive, yielding multiple potent and selective molecules at a much higher rate and more quickly than is reported for conventional drug discovery.
e-Therapeutics has a variety of preclinical stage assets, ETS2300, telomerase inhibition in anti-cancer; ETS3100, small molecule anti-TNF<ALPHA>; ETS2400, Hedgehog pathway inhibition; ETS5200, broad spectrum antivirals together with two immuno-oncology checkpoint projects.
The Company is fully funded to advance its drug discovery programmes. It is based in Oxford, UK. For more information, visit www.etherapeutics.co.uk.
This information is provided by RNS
The company news service from the London Stock Exchange
END
BOABIGDDLSBBGRU
(END) Dow Jones Newswires
February 16, 2017 02:00 ET (07:00 GMT)
1 Year E-therapeutics Chart |
1 Month E-therapeutics Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
